60 Degrees Pharmaceuticals Investor update
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hello, this is Craig Brelsford with RedChip Companies. Thank you for joining today's event with 60 Degrees Pharmaceuticals, which trades on the NASDAQ under the ticker SXTP. With us today, we have Geoff Dow, Chief Executive, President, and Director of 60 Degrees Pharmaceuticals. We will begin with a brief presentation in a moment, and then we will open the event to your questions. Welcome to everyone joining us today on X, YouTube, LinkedIn, and other social media platforms. To submit your question, we invite you to join us on Zoom. Use the posted event link. Once in Zoom, click the Q&A button at the bottom of your Zoom window and type your question into the text box. Before we begin, please allow me to read the safe harbor statement. This call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
All statements pertaining to future financial and/or operating results, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements. Forward-looking statements involve risks and uncertainties.
Geoff, please go ahead. Thank you, Craig, for the intro.
I am Geoff Dow, CEO of 60 Degrees Pharma, and thank you to those who have joined us this evening. I am going to be focused on some updates around our core mission, which is to develop new therapies for vector-borne disease. Specifically at the moment, we are focused on repositioning our commercial product, ARAKODA, for malaria prevention to a new tick-borne disease called babesiosis, which is transmitted by the same ticks as transmit Lyme disease, which everyone will be familiar with. It has been a couple of months since we did a webinar, so I just wanted to start with updating some key facts which can be derived from public data, but are just easier to present in a simple way. The first thing is our common shares outstanding in the top left is 4.5 million. Our market cap is around $2.5 million.
This slide has also been updated for the recent round of warrant inducement that we did as well. The ARAKODA sales snapshot here are our Q2 results, so we will not be reporting the Q3 until that comes out in the next week or so. Similarly with the financing and runway, I will add there that we have recently done a warrant inducement this week and raised some more cash. The effects of the outstanding warrants are listed there in the bottom right-hand side of the slide. Essentially, what we are doing at 60 Degrees Pharma is taking our commercially available product, ARAKODA. We do a bunch of different clinical and non-clinical studies to generate evidence, and then we go back to FDA to seek additional regulatory labeling for our existing product to expand its use case.
We are using the exact same chemistry, packaging, and everything in our commercial product. The only thing we really need is additional efficacy data for the new disease state. Before we get into the weeds on babesiosis, it is worth just highlighting why we are interested in vector-borne disease overall. For those of you who are unfamiliar with ticks, they transmit an array of different diseases, parasitic, bacterial, viral, and of course, alpha-gal. The same ticks can transmit all these diseases on the right-hand side of this slide. Of course, this year, everyone is familiar with the fact that we have hit record emergency room visits for tick bites. Tick-borne disease is a growing issue in the U.S., and there are no specific FDA-approved products to treat any of these indications. We have a portfolio focused on these vector-borne diseases.
Obviously, ARAKODA, the molecular name for that product is tafenoquine, and I will be making reference to that throughout the presentation. That is commercially available. We have a vet re-indication for the same molecule that we are working on for tick-borne disease in dogs. Our main R&D program for clinical disease is repositioning that same package for the treatment of human babesiosis, of which we have several studies that I will be discussing in a moment. We recently signed a deal with the University of Southern Mississippi to look at our second product, castanospermine, for alpha-gal. Then we are in the process of working through IP and licensing agreements for two other products, which we hope to announce in the near future. Babesiosis is the main focus of this discussion, and just a brief reminder, this is a parasite of red blood cells that is transmitted by ticks.
You have a life cycle in rodents. The ticks bite the mice, then they bite us, and then we get a developing cycle of parasite amplification in our red blood cells. That infection and red cell destruction leads to flu-like acute symptoms. It can cause other symptoms like weakness, loss of appetite, nausea. The red blood cell destruction can trigger hemolytic anemia, and in older adults, individuals with no spleen or who are immunocompromised, that can lead to severe disease. Finally, in those same people, you get a lot of drug resistance and relapsing, which can lead to a long-term illness characterized by persistent fatigue and other problems. For the purposes of today's discussion, we will be focusing on two major disease areas within babesiosis. The first one is severe disease, and by that we mean individuals who are hospitalized for their illness.
The issue in hospitalized folks is that the mortality rate can be 1% or 2% in immunocompetent patients, but up to 20% in patients with risk factors. The anemia in particular can lead to organ dysfunction and long recovery times, and it is a clinical emergency in older and high-risk patients. The unmet medical need here is the desire to have reduced morbidity and faster recovery. On the right-hand side of this slide, we have relapsing disease, and this is in patients who are immunosuppressed for various reasons, and do not have antibodies to Babesia, or they do not have a spleen, and so they cannot clear the infection as fast. The illness in these folks can last months to years and be refractory to treatment.
In some of our modeling, we've shown that, based on the literature cases, any individual treatment course of the standard of care, atovaquone and azithromycin, might only be effective 35% of the time, and you need multiple cycles of treatment. There's a lot of drug resistance and other issues. The unmet medical need here is durable parasite clearance. ARAKODA, just a little bit of information about it. We're treating this as a marketed tafenoquine safety platform where we can embrace the safety evidence and the formulation platform we already have to expand into other disease areas. The product, you could see the box on the left-hand side, it was approved by FDA in 2018 for use in malaria prevention in travelers, for adults who are traveling to Africa and need to protect themselves from malaria while away.
There's a weekly maintenance schedule after a load, and that differentiates it from other drugs that are daily. It also has the benefit of being quite broad spectrum, so it works against all the different malaria parasites everywhere in the world, and that simplicity of dosing makes it quite a compelling product. It was commercially launched in 2019, and that safety package consisted of eight randomized clinical studies involving about 1,100 patients at the approved dose. In post-marketing studies, we showed it was safe out to a year of dosing with a very similar adverse event profile to placebo, and no increased risk of psychiatric events, which is one of the things that people worry about with malaria drugs.
That known dosing platform, supported by that long weekly half-life allowing weekly dosing, also confers some real advantages as we think about babesiosis, which is a disease where you need to administer a drug for a long period of time. We think that babesiosis could triple the value of ARAKODA as an asset between now and when the malaria patents expire at the end of 2035. You could see that conveyed here on the right-hand side of this slide. Why do we think tafenoquine might be useful for babesiosis? Now I'm going to walk you through some of the background literature leading up to some of our recent data that we've reported for expanded access patients, and then I'll give you an update on where we are with the hospital study and future plans.
A group of folks from Yale in 2024 did some pretty interesting non-clinical work where they treated lethal Babesia infections in immunosuppressed mice with atovaquone, and you can see that on the left there, the red and blue curves, all the mice relapsed. In tafenoquine, there was relapse in a high inoculum treatment group, two relapsed, four cured. When you combine the two drugs together, as evidenced by those circles along the horizontal axis on the right-hand side, at both high and low inoculums, all of the animals were cured. This provided the rationale for atovaquone being combined with tafenoquine in immunosuppressed patients. That and other interesting data in the literature led to the publication of the first tafenoquine case series in 2024.
You can see here on the left-hand side a representative case where tafenoquine combined with atovaquone therapy led to clinical success. The first thing to note is that graph is a longitudinal time shot between 0 days and 350 days, so almost a year. The tafenoquine was added as that red horizontal bar at the bottom. That is the time course and timing. You could see that prior to that, there was a whole series of treatments given of various conventional medications, all of which failed. We know that because the closed circles show the level of or number of parasites in the blood, and then the boxes above the bars showing treatments, they are PCR results, and the negative ones represent clearance. You add tafenoquine to standard of care, and that is the first time this patient was cleared by PCR of parasitemia.
That was confirmed in four of five cases, using a regimen that is very similar to the malaria prevention dose, a loading dose of 600 followed by a weekly maintenance dose of 200 or 300 milligrams. This study also showed, based on other literature as well, that monotherapy was not sufficient, and where you saw the really strong clinical signal was when you combined tafenoquine with an atovaquone-containing regimen, mirroring what was seen in the prior animal studies. What I am showing here is a depiction of the treatment course of all the 45 cases of relapsing babesiosis that have been reported in the literature. You can see that it is really complicated, and you have periods of atovaquone therapy followed by treatment-free periods, and often those fail, and so you have to retreat.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
